<div id="readability-page-1"><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Connect Biopharma Holdings ( (CNTB) ) has shared an announcement. On April 23, 2026, Connect Biopharma reported that an independent Data Monitoring Committee completed a pre-specified interim efficacy analysis of its Phase 2 Seabreeze STAT trials in acute asthma and COPD, with no recommendation to change sample size. The committee also found no safety concerns, with no treatment-related serious or severe adverse events or discontinuations, allowing enrollment in both studies of rademikibart to proceed as planned. The company said rademikibart continues to be well tolerated and reiterated its plan to deliver topline data from both Seabreeze STAT studies in mid-2026. Management indicated it intends to move quickly to engage the U.S. Food and Drug Administration on a Phase 3 program, a step that could advance rademikibart’s prospects in the competitive market for biologic therapies targeting type 2 asthma and COPD exacerbations. The most recent analyst rating on (CNTB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Connect Biopharma Holdings stock, see the CNTB Stock Forecast page. Spark’s Take on CNTB Stock According to Spark, TipRanks’ AI Analyst, CNTB is a Neutral. The score is held back primarily by weak financial performance (zero 2025 revenue, sizable losses, and persistent cash burn), partially offset by a supportive technical trend (price above key moving averages with healthy—not overbought—momentum) and positive corporate events (new financing extending runway and encouraging trial readouts). Valuation provides limited support due to the negative P/E and no dividend yield. To see Spark’s full report on CNTB stock, click here. More about Connect Biopharma Holdings Connect Biopharma Holdings is a clinical-stage biopharmaceutical company focused on transforming care for asthma and chronic obstructive pulmonary disease, or COPD. Headquartered in San Diego, it is advancing rademikibart, a next-generation antibody targeting IL-4Rα, through global studies in acute exacerbations of asthma and COPD, and has licensed Greater China rights to Simcere Pharmaceutical with potential milestone and royalty revenues. The company’s strategy centers on addressing significant unmet need in type 2 inflammatory respiratory diseases. By positioning rademikibart as a potentially best-in-class therapy in acute exacerbations, Connect Biopharma aims to strengthen its presence in the competitive respiratory biologics market and build a commercial pathway via regional partnerships and future Phase 3 development. Average Trading Volume: 242,677 Technical Sentiment Signal: Buy Current Market Cap: $145.8M </div>

CNTB

Connect Biopharma Holdings (CNTB) announced that an independent Data Monitoring Committee completed a positive interim efficacy analysis of its Phase 2 Seabreeze STAT trials for rademikibart, with no safety concerns and no need to change sample size. The company plans to engage the FDA for a Phase 3 program and aims to deliver topline data in mid-2026. Analysts rate CNTB stock as a Buy with a $7.00 price target, though concerns about financial performance persist. Connect Biopharma focuses on treatments for asthma and COPD, positioning rademikibart as a leading therapy in the market.

Connect Biopharma Advances Rademikibart After Positive Interim Review